- Home
- ADPT vs CTO Comparison
ADPT vs CTO Comparison
Compare ADPT & CTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- CTO
- Stock Information
- Founded
- ADPT 2009
- CTO 1902
- Country
- ADPT United States
- CTO United States
- Employees
- ADPT N/A
- CTO N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- CTO Real Estate Investment Trusts
- Sector
- ADPT Health Care
- CTO Real Estate
- Exchange
- ADPT Nasdaq
- CTO Nasdaq
- Market Cap
- ADPT 514.3M
- CTO 444.4M
- IPO Year
- ADPT 2019
- CTO N/A
- Fundamental
- Price
- ADPT $4.27
- CTO $19.25
- Analyst Decision
- ADPT Buy
- CTO Strong Buy
- Analyst Count
- ADPT 5
- CTO 5
- Target Price
- ADPT $6.40
- CTO $20.70
- AVG Volume (30 Days)
- ADPT 985.1K
- CTO 474.0K
- Earning Date
- ADPT 08-01-2024
- CTO 10-24-2024
- Dividend Yield
- ADPT N/A
- CTO 7.90%
- EPS Growth
- ADPT N/A
- CTO N/A
- EPS
- ADPT N/A
- CTO 0.49
- Revenue
- ADPT $168,766,000.00
- CTO $115,327,000.00
- Revenue This Year
- ADPT $3.47
- CTO N/A
- Revenue Next Year
- ADPT $20.01
- CTO $10.79
- P/E Ratio
- ADPT N/A
- CTO $39.18
- Revenue Growth
- ADPT N/A
- CTO 19.62
- 52 Week Low
- ADPT $2.28
- CTO $15.63
- 52 Week High
- ADPT $6.86
- CTO $20.28
- Technical
- Relative Strength Index (RSI)
- ADPT 44.97
- CTO 53.65
- Support Level
- ADPT $4.49
- CTO $18.78
- Resistance Level
- ADPT $4.81
- CTO $19.53
- Average True Range (ATR)
- ADPT 0.27
- CTO 0.42
- MACD
- ADPT -0.07
- CTO -0.02
- Stochastic Oscillator
- ADPT 7.79
- CTO 56.57
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a Florida-based real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.